MCRB — Seres Therapeutics Share Price
Last trade - 00:00- $87.88m
- $57.08m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 6.38 | ||
| Price to Tang. Book | 6.38 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -140.97% | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 33.22 | 144.93 | n/a | n/a | n/a | 18.38 | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Seres Therapeutics, Inc. is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. It is developing SER-155, which has shown a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT and Fast Track designation to reduce the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT. SER-155 and the Company’s other pipeline programs are designed to target multiple disease-relevant pathways. In addition to allo-HSCT, it intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically patient populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities.
Directors
- Stephen Berenson CHM (60)
- Eric Shaff PRE (45)
- David Arkowitz CFO (59)
- Paula Cloghessy CHO (49)
- John Aunins EVP (60)
- David Ege EVP (47)
- Matthew Henn EVP (46)
- Thomas DesRosier EVP (66)
- Lisa von Moltke EVP (62)
- Teresa Young EVP (54)
- Marcus Chapman SVF (50)
- Dennis Ausiello IND (75)
- Gregory Behar IND (52)
- Paul Biondi IND (51)
- Willard Dere IND (67)
- Kurt Graves IND (53)
- Richard Kender IND (65)
- Meryl Zausner IND (64)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- October 18th, 2010
- Public Since
- June 26th, 2015
- No. of Shareholders
- 11
- No. of Employees
- 103
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 8,717,938
- Address
- 101 Cambridge Park Drive, CAMBRIDGE, 02140
- Web
- https://www.serestherapeutics.com/
- Phone
- +1 6179459626
- Contact
- Marella Thorell
- Auditors
- PricewaterhouseCoopers LLP
Latest News for MCRB
Upcoming Events for MCRB
Q1 2025 Seres Therapeutics Inc Earnings Call
Q1 2025 Seres Therapeutics Inc Earnings Release
Q2 2025 Seres Therapeutics Inc Earnings Release
Similar to MCRB
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
As of Today at 05:09 UTC, shares in Seres Therapeutics are trading at $10.08. This share price information is delayed by 15 minutes.
Shares in Seres Therapeutics last closed at $10.08 and the price had moved by -32.14% over the past 365 days. In terms of relative price strength the Seres Therapeutics share price has underperformed the S&P500 Index by -37.36% over the past year.
The overall consensus recommendation for Seres Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreSeres Therapeutics does not currently pay a dividend.
Seres Therapeutics does not currently pay a dividend.
Seres Therapeutics does not currently pay a dividend.
To buy shares in Seres Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $10.08, shares in Seres Therapeutics had a market capitalisation of $87.88m.
Here are the trading details for Seres Therapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: MCRB
Based on an overall assessment of its quality, value and momentum Seres Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Seres Therapeutics is $1,837.00. That is 18124.21% above the last closing price of $10.08.
Analysts covering Seres Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$119.50 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Seres Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -24.64%.
As of the last closing price of $10.08, shares in Seres Therapeutics were trading -40.2% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Seres Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $10.08.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Seres Therapeutics' management team is headed by:
- Stephen Berenson - CHM
- Eric Shaff - PRE
- David Arkowitz - CFO
- Paula Cloghessy - CHO
- John Aunins - EVP
- David Ege - EVP
- Matthew Henn - EVP
- Thomas DesRosier - EVP
- Lisa von Moltke - EVP
- Teresa Young - EVP
- Marcus Chapman - SVF
- Dennis Ausiello - IND
- Gregory Behar - IND
- Paul Biondi - IND
- Willard Dere - IND
- Kurt Graves - IND
- Richard Kender - IND
- Meryl Zausner - IND